Chapter 3 - THE LABORATORY WHERE MY NAME HAD BEEN ERASED
I did not return to the Upper East Side apartment.
Leo wanted me to come.
Every instinct told me to recover the notebook myself before Arthur destroyed it.
Miriam stopped me.
“You are not a police officer.”
“It is my work.”
“And that makes you emotionally vulnerable to acting without protection.”
“I am not unstable.”
“I did not say you were. I said the notebook matters enough that you might ignore your safety.”
She was right.
We provided Leo’s information to investigators and building security.
Arthur left the apartment twenty minutes later carrying two suitcases and a leather document case.
Rebecca waited downstairs in a black sedan.
The vehicle drove toward Connecticut.
Police did not stop them immediately.
Possessing a notebook associated with marital property was not automatically probable cause for roadside detention. The false patent documents, missing research records and financial transfers required verification.
Law moves more slowly than panic.
That can feel unbearable when the truth is traveling away from you.
Saint Catherine’s laboratory admitted me under temporary security clearance the following morning.
Daniel Brooks met me in the lobby.
He wore no dramatic expression.
Just concern sharpened by preparation.
“We have separated your research systems from the main network,” he said.
“Did you find the access path?”
“Your old tablet was used through a legacy emergency protocol.”
“That protocol required a security token.”
“Yes.”
“Mine remained in the hospital vault.”
“It was checked out eleven months ago.”
“By whom?”
He handed me the log.
My signature appeared beside the release.
I had not signed it.
The approving administrator was Dr. Leonard Vale, former vice president of research partnerships.
Leonard left Saint Catherine’s nine months earlier.
His new employer:
Aurelia Emergency Therapeutics.
“Malcolm recruited him,” Daniel said.
“Before Aurelia officially existed.”
“Yes.”
The conspiracy did not begin when Eleanor ordered me out.
It did not begin when Rebecca bought the ring.
Arthur and Malcolm had been positioning people inside the hospital for nearly a year.
Naomi waited inside the laboratory.
She showed me the empty notebook drawer.
No forced entry.
The lock had opened using Eleanor’s temporary visitor badge.
“Why did she have a badge?” Daniel asked.
“She visited me after surgery two years ago.”
“Was it still active?”
“It should not have been.”
Someone inside administration had reactivated it.
Security footage showed Eleanor entering through a service elevator six days earlier.
She wore sunglasses and carried a hospital volunteer tote bag.
Arthur walked behind her wearing a visitor mask.
They entered my office.
Twelve minutes later, Eleanor left with the tote bag heavier than before.
Arthur remained another six minutes.
During that time, he photographed my secure filing cabinet and removed the old tablet stored for destruction.
My mother-in-law, who once asked whether I counted pills, knew enough to steal the exact objects Malcolm needed.
“What else was in the drawer?” Daniel asked.
“Early patent correspondence.”
“Originals?”
“Copies.”
“Personal notes?”
“A photograph of my mother.”
Naomi touched my arm.
“We’ll recover what we can.”
The phrase sounded too much like loss.
I moved toward the experiment records.
“Show me the unauthorized download.”
The transferred data included more than the compound formula.
Manufacturing tolerances.
Known side effects.
Failed trial batches.
Emergency-use simulations.
Arthur and Rebecca had not taken only the promising results.
That was fortunate.
Anyone reading honestly would understand the drug remained experimental.
But Aurelia’s investor presentation did not describe uncertainty.
Its brochure called the compound:
A BREAKTHROUGH SYNTHETIC BLOOD SUBSTITUTE READY FOR RAPID DEPLOYMENT
It was not synthetic blood.
That description was scientifically false and medically dangerous.
The compound helped stabilize circulation temporarily.
It did not carry oxygen the way blood did.
Used incorrectly, it could delay necessary transfusion and create false confidence.
“Who wrote the brochure?” I asked.
“Rebecca’s communications team,” Naomi said.
Arthur’s mistress had transformed cautious science into a headline.
A private clinic called Haven Ridge Medical Center planned the demonstration.
The clinic specialized in executive wellness, experimental therapies and discreet treatment for wealthy clients.
It had no emergency-trauma unit.
The scheduled patient was described as a “volunteer with controlled blood-volume reduction.”
My stomach turned.
“They intend to remove blood from a healthy volunteer?”
Daniel answered carefully.
“The protocol submitted to the clinic describes a small controlled draw under medical supervision. But the presentation materials imply more.”
“Has an ethics board approved it?”
“The approval document appears to come from an independent board in Delaware.”
“Legitimate?”
“Under review.”
Naomi said:
“The clinic suspended the event after our notice.”
“Then why is Arthur driving there?”
“Because Malcolm moved the presentation.”
“Where?”
“A private research campus outside Hartford.”
The campus belonged to Voss Meridian Capital.
No public ethics filing.
No hospital oversight.
No transparency.
We notified authorities.
Then Arthur’s attorney delivered an injunction application accusing Saint Catherine’s of stealing Aurelia’s proprietary research.
Arthur claimed I developed the compound partly during unpaid evenings inside our marital home using financial support from his company.
That was false.
Arthur’s business nearly collapsed while I was conducting the research.
He contributed nothing.
Yet the allegation could slow release of records.
The hearing was scheduled for that afternoon.
Arthur appeared remotely from Connecticut.
Rebecca sat beside him.
The diamond ring remained on her hand.
Malcolm Voss occupied the other side of the table.
He looked like every investor who had ever described human risk as a temporary obstacle.
Arthur’s attorney argued that I had voluntarily assigned the research to Whitaker Family Holdings during a “period of marital cooperation.”
Miriam presented the prenuptial agreement, employment contracts and patent-development dates.
The judge asked Arthur:
“Did your wife sign the assignment in your presence?”
“Yes.”
“When?”
“Approximately four months ago.”
I was in Geneva during the stated week, presenting emergency-distribution research.
Travel records proved it.
Arthur changed the date.
Then Rebecca testified that she witnessed the signing at the apartment.
She claimed I invited her there as a corporate-relations adviser.
The apartment security log showed Rebecca had entered secretly using Arthur’s guest access.
Never while I was home.
The judge denied Aurelia’s immediate ownership claim and prohibited any clinical use pending regulatory review.
Arthur remained calm.
Too calm.
The private demonstration had never been his only plan.
At 4:30, Malcolm Voss announced that Aurelia had licensed the compound to Northstar Defense Medical Systems for fifty million dollars.
The licensing agreement was signed the previous night.
Northstar supplied emergency medicine to military and civilian disaster programs.
A false announcement could create national demand before ownership was resolved.
News sites repeated the claim within minutes.
NEW BLOOD SUBSTITUTE COULD REVOLUTIONIZE BATTLEFIELD CARE
My name did not appear.
Arthur was described as visionary founder.
Rebecca as strategic architect.
Malcolm as investor.
The woman whose notebook they stole had become an unnamed former researcher.
Then a junior laboratory technician named Nina Carter entered Naomi’s office.
She looked terrified.
“I copied the archive before they changed it.”
“Why?” I asked.
“Dr. Vale told me to delete the original failure data.”
“When?”
“Eight months ago.”
“Did you?”
“No.”
She handed Daniel a small encrypted drive.
“I thought they wanted to improve the presentation. Then I saw patient records.”
“What patient records?”
“Aurelia recruited people from a private rehabilitation hospital. They called them compensated volunteers.”
“How many?”
“Twelve.”
“Have they received the compound?”
“Not yet.”
“Where are they?”
Nina’s eyes filled.
“They were transferred to the Connecticut campus this morning.”
May you like
The investor demonstration had been canceled publicly.
Privately, Arthur and Malcolm still had twelve vulnerable people waiting inside a facility they controlled.
